A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

2,500

Participants

Timeline

Start Date

Not specified

Study Completion Date

November 30, 1996

Conditions
Pneumonia, Pneumocystis CariniiHIV Infections
Interventions
DRUG

Sulfamethoxazole-Trimethoprim

Trial Locations (24)

10011

Clinical Directors Network of Region II, New York

10037

Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York

10456

Bronx Lebanon Hosp Ctr, The Bronx

11201

Addiction Research and Treatment Corp, Brooklyn

19107

Philadelphia FIGHT, Philadelphia

19899

Wilmington Hosp / Med Ctr of Delaware, Wilmington

20422

Veterans Administration Med Ctr / Regional AIDS Program, Washington D.C.

21201

Baltimore Trials, Baltimore

Univ of Maryland at Baltimore, Baltimore

23298

Richmond AIDS Consortium, Richmond

30308

AIDS Research Consortium of Atlanta, Atlanta

48201

Comprehensive AIDS Alliance of Detroit, Detroit

48202

Henry Ford Hosp, Detroit

60657

AIDS Research Alliance - Chicago, Chicago

70112

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans

80204

Denver CPCRA / Denver Public Hlth, Denver

87131

Partners Research, Albuquerque

Univ Hosp / HIV - ID Clinic, Albuquerque

94110

Community Consortium of San Francisco, San Francisco

94305

Stanford Univ School of Medicine, Stanford

97210

Portland Veterans Adm Med Ctr / Rsch & Education Grp, Portland

98144

Univ of Washington / Pacific Med Ctr, Seattle

08103

Southern New Jersey AIDS Cln Trials / Dept of Med, Camden

07103

North Jersey Community Research Initiative, Newark

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Glaxo Wellcome

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000748 - A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients | Biotech Hunter | Biotech Hunter